TM Owner Gilead Sciences
Trodelvy IV 180mg Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- 'Trodelvy IV' is not a separate approved brand name - it is the same medicine as Trodelvy (sacituzumab govitecan-hziy) 180mg, made by Gilead Sciences (USA).
- Trodelvy is given only by intravenous infusion, so the 'IV' descriptor is redundant rather than marking a distinct formulation, and this catalogue entry should be treated as a likely duplicate of Trodelvy (see sr 3498) rather than a separate product.
- Under its real name, it is a Trop-2-directed antibody-drug conjugate approved in adults for unresectable, locally advanced or metastatic triple-negative breast cancer - as first-line therapy, alone or with pembrolizumab if PD-L1-positive, or after two or more prior systemic therapies - and for previously treated hormone-receptor-positive/HER2-negative metastatic breast cancer after endocrine therapy and at least two further treatment lines.
- An earlier accelerated approval for metastatic urothelial (bladder) cancer was voluntarily withdrawn by Gilead in the US in November 2024 and no longer applies.
- It is administered only in a hospital or clinic, never self-injected at home.
Side Effects
- Because this entry describes the same medicine as Trodelvy, its side-effect profile is identical: a boxed warning for severe, life-threatening or fatal neutropenia and for severe diarrhoea applies to every infusion.
- Blood counts are checked before each dose, and growth-factor support or dose delay is used for high-risk patients; diarrhoea is managed promptly with loperamide and fluids.
- Very common effects, in more than 1 in 10 patients, include nausea, fatigue, hair loss, vomiting, constipation, reduced appetite and abdominal pain, along with laboratory changes such as low neutrophil, white cell or red cell counts and raised blood sugar.
- Hypersensitivity and infusion-related reactions can occur during or shortly after infusion, especially in the first two cycles, so patients are monitored closely on the infusion unit.
- Report fever, signs of infection, or diarrhoea that does not settle to the care team immediately.
Precautions & Warnings
- Trodelvy (listed here as 'Trodelvy IV') is given only as an intravenous infusion by a healthcare professional experienced in oncology - there is no other route, and it is never self-administered.
- Full blood counts are checked at baseline and before every dose; treatment is delayed, reduced or stopped for significant neutropenia, severe diarrhoea, or other serious toxicity.
- Patients with reduced-function UGT1A1 genotypes may need closer monitoring for severe neutropenia.
- Severe hypersensitivity, including anaphylaxis, and interstitial lung disease/pneumonitis can occur and require treatment to be interrupted or stopped.
- Because it can harm an unborn baby, effective contraception is required during treatment and for a period afterward, and breastfeeding should be avoided during treatment and for one month after the last dose.
- Use with caution in hepatic impairment.
Avoid Interactions
- Do not combine this medicine with any other irinotecan-containing drug, since both share the same active metabolite, SN-38, raising the risk of toxicity.
- Strong or moderate UGT1A1 inhibitors, including certain antifungal and antiviral medicines, can increase side effects, while UGT1A1 inducers can reduce effectiveness - tell your oncology team about all such medicines.
- There are no known clinically important interactions with the anti-nausea or anti-diarrhoeal medicines commonly used to manage its side effects.
- Always disclose every prescription, herbal and over-the-counter medicine, including HIV antiviral therapy, to your care team before each infusion.
References
Frequently Asked Questions
No. 'Trodelvy IV' is not a distinct approved brand - it is the same medicine as Trodelvy (sacituzumab govitecan), which is only ever given by intravenous infusion. Ask your care team to confirm you are receiving standard Trodelvy; there is no separate 'IV' version to compare it with.
Trodelvy is given only as an intravenous infusion in a hospital or clinic, typically on days 1 and 8 of a 21-day cycle. The first infusion runs about 3 hours; later ones can be shortened to 1 to 2 hours if well tolerated.
Trodelvy's boxed warning covers severe or fatal low white blood cell counts (neutropenia) and severe diarrhoea. Very common effects include nausea, tiredness, hair loss and vomiting. Tell your care team at once about fever, ongoing diarrhoea, or signs of infection.
Avoid any other irinotecan-containing medicine, since Trodelvy shares its active breakdown product, SN-38. Tell your oncology team about antifungal, antiviral and HIV medicines you take, as some can increase side effects. Effective contraception is required during treatment.
Blood counts are checked before each dose, then Trodelvy is given through a vein while staff watch for infusion reactions, especially in the first two cycles. You may receive anti-nausea medicine beforehand, and the dose can be delayed or lowered if side effects occur.
Trodelvy treats adults with triple-negative breast cancer, either early-line or after prior chemotherapy, and hormone-receptor-positive, HER2-negative breast cancer after endocrine therapy and further treatment. A previous bladder cancer approval was withdrawn in the US in 2024.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
